Clostridium difficile infection is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system.
Dr Christina Surawicz and colleagues from Washington, USA reported that patients with Clostridium difficile infection typically have extended lengths-of-stay in hospitals, and Clostridium difficile infection is a frequent cause of large hospital outbreaks of disease.
This guideline provides recommendations for the diagnosis and management of patients with Clostridium difficile infection as well as for the prevention and control of outbreaks while supplementing previously published guidelines.
The research team reported that the new molecular diagnostic stool tests will likely replace current enzyme immunoassay tests.
|Therapy with metronidazole remains the choice for mild-to-moderate disease|
|American Journal of Gastroenterology |
The research team suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease.
The team reported that therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease.
Dr Surawicz 's team commented, "We propose a classification of disease severity to guide therapy that is useful for clinicians."
"We review current treatment options for patients with recurrent Clostridium difficile infection and recommendations for the control and prevention of outbreaks of Clostridium difficile infection ."